May 7, 2026
Analysis
Angelini Pharma's $4.1 Billion Acquisition of Catalyst Pharmaceuticals: A Strategic Move
Angelini Pharma's $4.1 billion acquisition of Catalyst Pharmaceuticals strengthens its position in brain health, signaling significant M&A trends.
By Marcus Rivera
Earnings
ESAB Corporation's Q1 2026 Financial Results: A Closer Look
ESAB Corporation reports Q1 2026 results, revealing key insights into industrial equipment demand and market positioning.
Sarah Chen
Markets
Critical Metals Corp Gains Approval for Strategic Rare Earth Acquisition in Greenland
Marcus Rivera
Analysis
Apollo Funds' Strategic Acquisition of Prosol Group: Insights for Investors
Apollo Funds' acquisition of Prosol Group signals a significant shift towards defensive investments in the food sector.
James McAllister
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Earnings
Pfizer Surprises Markets with Strong Q1 Earnings Despite COVID Revenue Decline
Sarah Chen • May 5
Markets
TWFG Insurance's APIA Acquisition: Expanding Specialty Insurance Market Presence
Catherine Walsh • May 5
Analysis
United-American Airlines Merger: A Bold Vision Amid Regulatory Hurdles
Tyler Brooks • May 5
Markets
Bullish's $4.2 Billion Acquisition of Equiniti: A Game Changer for Tokenized Securities
Diana Kowalski • May 5
Analysis
KKR's Acquisition of Arctos Partners: A Strategic Move in Sports Investment
Marcus Rivera • May 5
Markets
Investment Community Raises Concerns Over Potential GameStop-eBay Merger
James McAllister • May 5
